Pharmacogenetic Test

Definition

Examines how your genes affect the way your body responds to certain medicines. In a blood, saliva or cheek swab sample, it detects gene variants that affect the absorption, breakdown and effectiveness of drugs.

Purpose, for which drugs and conditions:

AreaGeneDrug/Condition
High cholesterolSLCO1B1Statin tolerance
DepressionCYP2D6 / CYP2C19Antidepressant metabolism
Clot prevention,Warfarin dose adjustment
HIVHLA-B, CYP2B6Side effect prediction
Multiple sclerosisTPMT / NUDT15Azathioprine response
Cancer treatmentHER2Trastuzumab
TPMTMercaptopurine
UGT1A1Irinotecan

Results

The result report describes the changes in the gene and helps the physician recommend the appropriate treatment or dose.

Terms you will see in the report, CPIC standard terminology

The terms used in pharmacogenetic reports have been standardized by the Clinical Pharmacogenetics Implementation Consortium (CPIC). In a study conducted with 58 experts using the Delphi method, 90% of the experts reached consensus on the final set of terms.

Enzyme activity phenotypes (for drug-metabolizing enzymes such as CYP2D6, CYP2C19, TPMT, DPYD), expert consensus 91.7%:

TermMeaning
Ultrarapid metabolizer (Ultrarapid)The enzyme works much faster than expected
Normal metabolizer (Normal)Expected enzyme activity. Formerly called "extensive metabolizer", this term has been abandoned
Intermediate metabolizer (Intermediate)Reduced activity
Poor metabolizer (Poor)Markedly reduced or almost no activity

Allele function terms:

TermMeaning
Increased function (Increased function)Increased enzyme activity
Normal function (Normal function)Normal enzyme activity
Decreased function (Decreased function)Decreased enzyme activity
No function (No function)No enzyme activity
Uncertain function (Uncertain function)No literature defining the function
Conflicting function (Conflicting function)Data on the function are conflicting

Why it was standardized: Different terms were being used for different laboratories and genes. The CPIC standard makes reports comparable across laboratories and allows them to be shared consistently in electronic health records.

Note for the glossary: The terminology used in Genetiks' pharmacogenetic reports should be confirmed. If the CPIC standard is used, the table above applies directly; if not, the laboratory's own terms should be mapped to it.

Risks and Limitations

A frequently misunderstood point:

The test cannot diagnose any disease and cannot provide information about your risk of developing a disease. The results show how medicines may affect you; they do not provide information about your health status.

In other words, a pharmacogenetic test is not a "genetic disease screening"; it only provides information about drug response.

Related Tests